This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.
The pharma companies shedding value amid Trump trade-off
Previous Co-pay cut ‘an investment in productivity’: Twomey
Next ‘Methylamphetamine is a scourge in our community’
Related Posts
Pfizer sues pharmas over arthritis drug patent
If successful, action could hit pharmacy dispensed biosim Brenzys Multinational pharmaceutical giant Pfizer is suing four other drug companies over allegedly breaching a patent for its rheumatoid arthritis treatment Enbrel (etanercept) by selling biosimilars of the blockbuster drug. If ultimately successful it could potentially lead to the withdrawal of Brenzys,…
The big money
Which are the richest pharmaceuticals companies in the world? And how much do they earn? Despite a number of mergers, sell-offs, buyouts and the emergence of some new specialist blockbuster drugs the world's leading pharmaceutical companies have remained fairly constant, a new report reveals. In its recently released report of the…
Regulatory barriers may not be enough to stop CWH, Sigma merger
Sigma Healthcare’s merger with Chemist Warehouse may go ahead despite competition concerns Associate Professor of Finance at RMIT, Angel Zhong, warns Corporate Australia loves a big merger. And amid a growing flurry of them across the business scene, a new blockbuster has emerged. All eyes are on two titans of the pharmacy…